Novonesis A/s Class B · OMXCOP:NSIS_B
Novonesis A/s Class B — Novozymes — Q1 2015 Earnings Presentation
59 slides from Novonesis A/s Class B's earnings presentation, Apr 23, 2015
Slide 1: Roadshow Presentation Q1 2015
ROADSHOW PRESENTATION Q1 2015 April 23, 2015
Slide 2: Table of Contents
Table of Contents Table of Contents 2 1. Q4 2014 presentation 4-8 2. Novozymes Overview 9-15 3. Strategy 16-25 4. Segmental Overview 26 Household Care 27-30 Food & Beverages 31-32 Bioenergy 33-36 Agriculture & Feed 37-41 Technical & Pharma 42-44 5. Sustainability 45-51 6. Financial Review
Slide 3: Forward-Looking Statements
Forward-Looking Statements This presentation and its related comments contain forward-looking statements, including statements about future events, future financial performance, plans, strategies and expectations. Forward-looking statements are associated with words such as, but not limited to, "bel
Slide 4: Quarterly Results
QUARTERLY RESULTS • NOVOZYMES OVERVIEW • STRATEGY • SEGMENTAL OVERVIEW • SUSTAINABILITY • FINANCIAL REVIEW QUARTERLY RESULTS QUARTERLY RESULTS • OVERVIEW • STRATEGY • SEGMENTAL OVERVIEW • SUSTAINABILITY • FINANCIAL REVIEW
Slide 5: Q1 2015 Summary
Q1 2015 Summary Q1 2015 – overall in line with expectations Sales and organic growth • 8% organic sales growth, in line with expectations. Q1 2013 – Q1 2015 DKKm Sales up 18% in DKK compared with Q1 2014 12% 11% 4,000 • Strong growth in Agriculture & Feed – driven both 10% 3,579 3,000 by performance
Slide 6: Volatility in Household Care
Volatility in Household Care Household Care: growth fluctuates Current trading environment Quarterly organic growth rates, 2008-2015 1. Dynamic North American market with 30% trading-down and strong competition among detergent producers creates 20% challenging market and focus on cost reduction of f
Slide 7: Sales & Markets
Sales & Markets Q1 2015 sales: DKK +18%, organic +8% Sales by industry, DKKm Q1 2015 Q1 2014 • Household Care: Strong comparison in Q1 2014. Soft Household 1,127 Latin America sales. Dynamic consumer market +4%/-2% Care 1,080 tempers growth in North America • Food & Beverages: Good performance acr
Slide 8: Q1 2015 Financial Performance & Outlook
Q1 2015 Financial Performance & Outlook Satisfactory financial performance 2015 2015 Realized Outlook Outlook • Gross margin on par with Q1 2014 Key financials Q1 2015 Apr. 23 Jan. 20 • Disregarding the net one-time impact from The BioAg Sales growth, org. +8% 7-9% 7-9% Alliance, EBIT grew by ~20%,
Slide 9: Overview
QUARTERLY RESULTS • NOVOZYMES OVERVIEW • STRATEGY • SEGMENTAL OVERVIEW • SUSTAINABILITY • FINANCIAL REVIEW INVESTOR PRESENTATION OVERVIEW QUARTERLY RESULTS • OVERVIEW • STRATEGY • SEGMENTAL OVERVIEW • SUSTAINABILITY • FINANCIAL REVIEW
Slide 10: Novozymes – The World Leader in Bioinnovation
QUARTERLY RESULTS • NOVOZYMES OVERVIEW • STRATEGY • SEGMENTAL OVERVIEW • SUSTAINABILITY • FINANCIAL REVIEW Novozymes – The World Leader in Bioinnovation Who are we? Founded 1925 Listed 2000 Global: ~6,500 employees, 700 products in 140 countries Ticker NZYM B Exchange Copenhagen Market Cap* US$ ~15b
Slide 11: Experienced Leadership Team
QUARTERLY RESULTS • NOVOZYMES OVERVIEW • STRATEGY • SEGMENTAL OVERVIEW • SUSTAINABILITY • FINANCIAL REVIEW Experienced Leadership Team Peder Holk Nielsen Thomas Videbæk Per Falholt Benny Loft Thomas Nagy Andrew Fordyce Per Falholt Peder Holk Nielsen Andrew Fordyce Executive Vice President, President
Slide 12: Delivering Tomorrow's Solutions Today
QUARTERLY RESULTS • NOVOZYMES OVERVIEW • STRATEGY • SEGMENTAL OVERVIEW • SUSTAINABILITY • FINANCIAL REVIEW Delivering Tomorrow’s Solutions Today Delivering solutions from Helping companies This unique approach nature: become more efficient: leads to: food applications, detergents, energy efficiency,
Slide 13: Uniquely Diversified Group - Creates Synergies and New Opportunities
QUARTERLY RESULTS • NOVOZYMES OVERVIEW • STRATEGY • SEGMENTAL OVERVIEW • SUSTAINABILITY • FINANCIAL REVIEW Uniquely Diversified Group - Creates Synergies and New Opportunities • Unique biotech-focused business with a strong legacy of delivering growth, earnings, and cash flow • ~14% of annual sales
Slide 14: Diversification in Revenue Streams Underpins Strong Financial Position
QUARTERLY RESULTS • NOVOZYMES OVERVIEW • STRATEGY • SEGMENTAL OVERVIEW • SUSTAINABILITY • FINANCIAL REVIEW Diversification in Revenue Streams Underpins the Company’s Strong Financial Position Industry growth profiles and 5-yr org. CAGRs Region growth profiles and 5-yr LCY CAGRs 5 5 HHC 9% EMEA 8% 4
Slide 15: Global Production and R&D Setup
QUARTERLY RESULTS • NOVOZYMES OVERVIEW • STRATEGY • SEGMENTAL OVERVIEW • SUSTAINABILITY • FINANCIAL REVIEW Global Production and R&D Setup Milwaukee, Wisconsin BioAg production Nottingham, England Bagsværd, Denmark Saskatoon, Canada Biopharma production Headquarters BioAg production (Albumin
Slide 16: Strategy
QUARTERLY RESULTS • NOVOZYMES OVERVIEW • STRATEGY • SEGMENTAL OVERVIEW • SUSTAINABILITY • FINANCIAL REVIEW INVESTOR PRESENTATION STRATEGY QUARTERLY RESULTS • OVERVIEW • STRATEGY • SEGMENTAL OVERVIEW • SUSTAINABILITY • FINANCIAL REVIEW
Slide 17: Novozymes' Purpose
QUARTERLY RESULTS • NOVOZYMES OVERVIEW • STRATEGY • SEGMENTAL OVERVIEW • SUSTAINABILITY • FINANCIAL REVIEW Novozymes’ Purpose 17
Slide 18: Novozymes' Strategy
QUARTERLY RESULTS • NOVOZYMES OVERVIEW • STRATEGY • SEGMENTAL OVERVIEW • SUSTAINABILITY • FINANCIAL REVIEW Novozymes’ Strategy FOCUS AREAS 18
Slide 19: Long term financial targets, 2015-2020
QUARTERLY RESULTS • NOVOZYMES OVERVIEW • STRATEGY • SEGMENTAL OVERVIEW • SUSTAINABILITY • FINANCIAL REVIEW Long term financial targets, 2015-2020 10-year organic sales growth Organic sales growth: 8-10% 14% Sales DKKm Growth 15,000 12% 12,000 10% EBIT margin: ≥ 26% 8% 6% 9,000 6,000 4% 3,000 2% ROIC
Slide 20: Undisputed Market Leader Expanding Enzyme Application
QUARTERLY RESULTS • NOVOZYMES OVERVIEW • STRATEGY • SEGMENTAL OVERVIEW • SUSTAINABILITY • FINANCIAL REVIEW Undisputed Market Leader Expanding Enzyme Application Global enzyme market value: 2000: 2014: Global enzyme market value USD ~ 2.0bn USD ~ 4.0 bn 2014: USD ~ 4.0 bn Novozymes Rest of Novozymes
Slide 21: Innovation Drives Top-Line Growth
QUARTERLY RESULTS • NOVOZYMES OVERVIEW • STRATEGY • SEGMENTAL OVERVIEW • SUSTAINABILITY • FINANCIAL REVIEW Innovation Drives Top-Line Growth • Achieving growth through R&D investment is the cornerstone of business model • >50 new product in the last 5 years, ~100 active projects in current portfolio
Slide 22: Developing new technology and business platforms
QUARTERLY RESULTS • NOVOZYMES OVERVIEW • STRATEGY • SEGMENTAL OVERVIEW • SUSTAINABILITY • FINANCIAL REVIEW Developing new technology and business platforms Continued development in …creates opportunities to develop our technology base… new business platform Biomass Strain development using conversio
Slide 23: Business Development Nurtures Tomorrow's Business for Novozymes
QUARTERLY RESULTS • NOVOZYMES OVERVIEW • STRATEGY • SEGMENTAL OVERVIEW • SUSTAINABILITY • FINANCIAL REVIEW Business Development Nurtures Tomorrow’s Business for Novozymes • Responsible for new business areas and Novozymes’ entire pipeline prioritization • Close coordination on pipeline, resource all
Slide 24: Fermentation Technology - 3 Levers to Improve Profitability
QUARTERLY RESULTS • NOVOZYMES OVERVIEW • STRATEGY • SEGMENTAL OVERVIEW • SUSTAINABILITY • FINANCIAL REVIEW Fermentation Technology - 3 Levers to Improves Profitability • All of Novozymes’ solutions are produced via fermentation • Dedicated R&D investment (15-20% of R&D investment) goes to improving
Slide 25: Cash Generation, Use, Capex and Future Priorities
QUARTERLY RESULTS • NOVOZYMES OVERVIEW • STRATEGY • SEGMENTAL OVERVIEW • SUSTAINABILITY • FINANCIAL REVIEW Cash Generation, Use, Capex and Future Priorities – DKK billion Cash generation has tracked EBIT Cash for growth and shareholders 5.0 4.0 3.5 4.0 3.0 3.0 2.5 2.0 2.0 1.5 1.0 1.0 0.5 0.0 0.0 EBI
Slide 26: Segmental Overview
QUARTERLY RESULTS • NOVOZYMES OVERVIEW • STRATEGY • SEGMENTAL OVERVIEW • SUSTAINABILITY • FINANCIAL REVIEW INVESTOR PRESENTATION SEGMENTAL OVERVIEW QUARTERLY RESULTS • OVERVIEW • STRATEGY • SEGMENTAL OVERVIEW • SUSTAINABILITY • FINANCIAL REVIEW
Slide 27: Household Care Overview – 35% of sales in 2014
QUARTERLY RESULTS • NOVOZYMES OVERVIEW • STRATEGY • SEGMENTAL OVERVIEW • SUSTAINABILITY • FINANCIAL REVIEW Household Care Overview – 35% of sales in 2014 Household Care Sales Sales DKKm ORG growth Applications Laundry & dishwasher detergents 4,222 4,353 40% 5,0 00 3,973 4,7 50 4,5 00 35% 3,514 4,2 5
Slide 28: Three distinct growth paths in Household Care
QUARTERLY RESULTS • NOVOZYMES OVERVIEW • STRATEGY • SEGMENTAL OVERVIEW • SUSTAINABILITY • FINANCIAL REVIEW Three distinct growth paths in Household Care Emerging Markets Penetrate new brands & segments with broader portfolio of solutions at different performance levels to unlock high volume market a
Slide 29: Large opportunity for increasing enzyme inclusion in every wash load
QUARTERLY RESULTS • NOVOZYMES OVERVIEW • STRATEGY • SEGMENTAL OVERVIEW • SUSTAINABILITY • FINANCIAL REVIEW Large opportunity for increasing enzyme inclusion in every wash load Enzyme spend index per wash load All European high performance detergents contain enzymes, 2008 2014 but over time enzyme in
Slide 30: Growth in household care driven by all tiers
QUARTERLY RESULTS • NOVOZYMES OVERVIEW • STRATEGY • SEGMENTAL OVERVIEW • SUSTAINABILITY • FINANCIAL REVIEW Growth in household care driven by all tiers New innovation Spend on enzymes as % of raw New innovation to expand share of material costs, anno 2014 raw-materials bill by improving 14% performa
Slide 31: Food & Beverages Overview – 26% of sales in 2014
QUARTERLY RESULTS • NOVOZYMES OVERVIEW • STRATEGY • SEGMENTAL OVERVIEW • SUSTAINABILITY • FINANCIAL REVIEW Food & Beverages Overview – 26% of sales in 2014 Food & Beverages Sales Sales DKKm ORG growth Baking / Starch conversion / 4,5 00 4,2 50 40% Applications Brewing / Beverage alcohol / 3,278 35%
Slide 32: Fill and Manage the Pipeline - Enzyme Innovation to the Food Industry
QUARTERLY RESULTS • NOVOZYMES OVERVIEW • STRATEGY • SEGMENTAL OVERVIEW • SUSTAINABILITY • FINANCIAL REVIEW Fill and Manage the Pipeline - Enzyme Innovation to the Food Industry Informed New economies Health & Wellbeing Convenience consumption and urbanization Reinforce customers’ Reduce costs Apply
Slide 33: Bioenergy Overview – 18% of sales in 2014
QUARTERLY RESULTS • NOVOZYMES OVERVIEW • STRATEGY • SEGMENTAL OVERVIEW • SUSTAINABILITY • FINANCIAL REVIEW Bioenergy Overview – 18% of sales in 2014 Bioenergy Sales Sales DKKm ORG growth Corn ethanol / Biomass Applications 3,0 00 60% conversion 2,270 2,7 50 50% 2,5 00 1,846 1,782 1,909 Novozymes 2,2
Slide 34: Bioenergy Strategy Overview
QUARTERLY RESULTS • NOVOZYMES OVERVIEW • STRATEGY • SEGMENTAL OVERVIEW • SUSTAINABILITY • FINANCIAL REVIEW Bioenergy Strategy Overview Grain Ethanol (1G) Biomass Conversion (2G) New Opportunities - Drive more yield - Enable commercialization - Explore biodiesel and sugar cane 3.00 gal/bu Total produ
Slide 35: Production of Biofuels and Beyond
QUARTERLY RESULTS • NOVOZYMES OVERVIEW • STRATEGY • SEGMENTAL OVERVIEW • SUSTAINABILITY • FINANCIAL REVIEW Production of Biofuels and Beyond Raw material Production process End product Sugarcane Extraction Ethanol Co-products Bagasse; Energy Fermentable sugar Classical Butanol Milling Cooking Enzyme
Slide 36: NZ Supplies 5 Out of the 7 Commercial Cellulosic Ethanol Plants
QUARTERLY RESULTS • NOVOZYMES OVERVIEW • STRATEGY • SEGMENTAL OVERVIEW • SUSTAINABILITY • FINANCIAL REVIEW NZ Supplies 5 Out of the 7 Commercial Cellulosic Ethanol Plants Currently Operating • 2014 was a breakthrough year with 6 commercially operating 2G plants at year-end • Important to show techni
Slide 37: Agriculture & Feed Overview – 14% of sales in 2014
QUARTERLY RESULTS • NOVOZYMES OVERVIEW • STRATEGY • SEGMENTAL OVERVIEW • SUSTAINABILITY • FINANCIAL REVIEW Agriculture & Feed Overview – 14% of sales in 2014 Agriculture & Feed Sales Feed alliance The BioAg Alliance Sales DKKm ORG growth 3,0 00 40% 2,7 50 35% 2,5 00 2,2 50 30% Enzymes for nutritive
Slide 38: BioAg; Niche Market with Significant Opportunities
QUARTERLY RESULTS • NOVOZYMES OVERVIEW • STRATEGY • SEGMENTAL OVERVIEW • SUSTAINABILITY • FINANCIAL REVIEW BioAg; Niche Market with Significant Opportunities AG BIOLOGICALS MARKET1 AG MICROBIALS MARKET1 MARKET SEGMENTED BY PRODUCT CLASS MARKET SEGMENTED BY CROP Microbial Pesticides 2/3rd Fruits
Slide 39: The BioAg Alliance - The Industry's Most Advanced Microbial Platform
QUARTERLY RESULTS • NOVOZYMES OVERVIEW • STRATEGY • SEGMENTAL OVERVIEW • SUSTAINABILITY • FINANCIAL REVIEW The BioAg Alliance - The Industry's Most Advanced Microbial Platform ESTABLISHED MICROBIAL LEADERSHIP • World leader in microbial technology; discovery, development and production + INDUSTRY-LE
Slide 40: Power of Microbial Technology: Proven Microbial Portfolio
QUARTERLY RESULTS • NOVOZYMES OVERVIEW • STRATEGY • SEGMENTAL OVERVIEW • SUSTAINABILITY • FINANCIAL REVIEW Power of Microbial Technology: Novozymes’ Proven Microbial Portfolio CURRENT PRODUCT PORTFOLIO 1 2 Biocontrol Inoculants products Nutrient Nitrogen Biofungicides Bioinsecticides efficiency fixa
Slide 41: Attractive Value Propositions in Animal Feed
QUARTERLY RESULTS • NOVOZYMES OVERVIEW • STRATEGY • SEGMENTAL OVERVIEW • SUSTAINABILITY • FINANCIAL REVIEW Attractive Value Propositions in Animal Feed Phytase – phosphate • Only 3-30%* of phosphate in feed is available to the animal • Ronozyme NP® releases half of the phosphate bound – Ronozyme HiP
Slide 42: Technical & Pharma Overview – 7% of sales in 2014
QUARTERLY RESULTS • NOVOZYMES OVERVIEW • STRATEGY • SEGMENTAL OVERVIEW • SUSTAINABILITY • FINANCIAL REVIEW Technical & Pharma Overview – 7% of sales in 2014 Technical & Pharma Sales Sales DKKm ORG growth Textiles / Leather / Pulp & Paper 60% Applications Albumin / Hyaluronic acid / 1,5 00 1,2 50 50%
Slide 43: Pharma Overview. Four technology offerings
QUARTERLY RESULTS • NOVOZYMES OVERVIEW • STRATEGY • SEGMENTAL OVERVIEW • SUSTAINABILITY • FINANCIAL REVIEW Pharma Overview. Four technology offerings The classic pharma value chain Drug Sales and Drug Discovery Manufacturing Distribution Development Marketing Novozymes Existing business Emerging bus
Slide 44: Multiple opportunities and potential revenue streams in Pharma from Albumin
QUARTERLY RESULTS • NOVOZYMES OVERVIEW • STRATEGY • SEGMENTAL OVERVIEW • SUSTAINABILITY • FINANCIAL REVIEW Multiple opportunities and potential revenue streams in Pharma from Albumin Partner Drug PI PII PIII MA Market Tanzeum/Eperzan (Albiglutide) - GLP1 for Diabetes rIX-FP - Once weekly for Hemophi
Slide 45: Sustainability & Corp. Governance
QUARTERLY RESULTS • NOVOZYMES OVERVIEW • STRATEGY • SEGMENTAL OVERVIEW • SUSTAINABILITY • FINANCIAL REVIEW INVESTOR PRESENTATION SUSTAINABILITY & CORP. GOVERNANCE QUARTERLY RESULTS • OVERVIEW • STRATEGY • SEGMENTAL OVERVIEW • SUSTAINABILITY • FINANCIAL REVIEW
Slide 46: Three-pronged Core of Novozymes' Sustainability
QUARTERLY RESULTS • NOVOZYMES OVERVIEW • STRATEGY • SEGMENTAL OVERVIEW • SUSTAINABILITY • FINANCIAL REVIEW Three-pronged Core of Novozymes’ Sustainability Economic growth Use of natural resources It’s all in the numbers Scientific - All products are life-cycle assessed (LCA) Bioinnovation approach -
Slide 47: Decoupling Revenue and Profit Growth from Resource Consumption
QUARTERLY RESULTS • NOVOZYMES OVERVIEW • STRATEGY • SEGMENTAL OVERVIEW • SUSTAINABILITY • FINANCIAL REVIEW Decoupling Revenue and Profit Growth from Ressource Consumption 120% Sales 100% % change from 2005 baseline Gross 80% Profit 60% Water 40% Energy 20% 0% CO2 CO2 2005 2006 2007 2008 2009 2010 20
Slide 48: New sustainability targets - measuring our progress
QUARTERLY RESULTS • NOVOZYMES OVERVIEW • STRATEGY • SEGMENTAL OVERVIEW • SUSTAINABILITY • FINANCIAL REVIEW New sustainability targets - measuring our progress… Impact Targets REACH EDUCATE CATALYZE six billion people with our one million people about five global partnerships biological solutions the
Slide 49: Remuneration Principles for Executive Leadership
QUARTERLY RESULTS • NOVOZYMES OVERVIEW • STRATEGY • SEGMENTAL OVERVIEW • SUSTAINABILITY • FINANCIAL REVIEW Remuneration Principles for Executive Leadership • Novozymes’ principles for Executive Leadership remuneration ensure close alignment with long-term shareholder interests, links remuneration to
Slide 50: Reducing CO2 Emissions Together with our Customers
QUARTERLY RESULTS • NOVOZYMES OVERVIEW • STRATEGY • SEGMENTAL OVERVIEW • SUSTAINABILITY • FINANCIAL REVIEW Reducing CO2 Emissions Together with our Customers • In 2014, Novozymes helped customers save 60 million tons of CO2 through the application of Novozymes’ products, equivalent to taking 25 mill
Slide 51: Sustainability Performance and Targets
QUARTERLY RESULTS • NOVOZYMES OVERVIEW • STRATEGY • SEGMENTAL OVERVIEW • SUSTAINABILITY • FINANCIAL REVIEW Sustainability Performance and Targets 2014 2014 Targets targets realized Water efficiency (index 2005) 34% 37% Energy efficiency (index 2005) 42% 43% CO2 efficiency (index 2005) >50% 56% Milli
Slide 52: Financial Review
QUARTERLY RESULTS • NOVOZYMES OVERVIEW • STRATEGY • SEGMENTAL OVERVIEW • SUSTAINABILITY • FINANCIAL REVIEW INVESTOR PRESENTATION FINANCIAL REVIEW QUARTERLY RESULTS • OVERVIEW • STRATEGY • SEGMENTAL OVERVIEW • SUSTAINABILITY • FINANCIAL REVIEW
Slide 53: Historical Performance Demonstrates Track Record of Delivery – I/II
QUARTERLY RESULTS • NOVOZYMES OVERVIEW • STRATEGY • SEGMENTAL OVERVIEW • SUSTAINABILITY • FINANCIAL REVIEW Historical Performance Demonstrates Track Record of Delivery – I/II 2000-2014 sales CAGR of ~7% Gross margin 60% 20% Sales DKKm Growth 15,000 58% 57.2% 16% 12,000 56.2% 55.6% 57.4% 56% 57.2% 12
Slide 54: Historical Performance Demonstrates Track Record of Delivery – II/II
QUARTERLY RESULTS • NOVOZYMES OVERVIEW • STRATEGY • SEGMENTAL OVERVIEW • SUSTAINABILITY • FINANCIAL REVIEW Historical Performance Demonstrates Track Record of Delivery – II/II NIBD CAPEX 1.0 NIBD DKKm 2,500 16% 1,500 Capex DKKm CAPEX/sales 0.8 2,000 14% NIBD/EBITDA 1,200 0.6 1,500 12% 900 0.4 1,000
Slide 55: Low Exposure to Raw Material Fluctuations
QUARTERLY RESULTS • NOVOZYMES OVERVIEW • STRATEGY • SEGMENTAL OVERVIEW • SUSTAINABILITY • FINANCIAL REVIEW Low Exposure to Raw Material Fluctuations Split of COGS • Factors impacting COGS development: • Productivity improvements, input prices, currency • Note: accounting practice implies that 35% th
Slide 56: Dividend and Stock Buyback History
QUARTERLY RESULTS • NOVOZYMES OVERVIEW • STRATEGY • SEGMENTAL OVERVIEW • SUSTAINABILITY • FINANCIAL REVIEW Dividend and Stock Buyback History • DKK 3.00 dividend per share paid out for 2014 Dividend / Buybacks up 20%, payout ratio 36.6% DKK million Dividend per share, DKK Dividend Buyback DPS • Di
Slide 57: Shareholder Distribution
QUARTERLY RESULTS • NOVOZYMES OVERVIEW • STRATEGY • SEGMENTAL OVERVIEW • SUSTAINABILITY • FINANCIAL REVIEW Shareholder Distribution B shares listed in Copenhagen Shareholder distribution of under the symbol “NZYM B” B common stock* • Two share classes; A and B shares Rest of • B shares listed in Cop
Slide 58: Investor Relations Contacts
QUARTERLY RESULTS • NOVOZYMES OVERVIEW • STRATEGY • SEGMENTAL OVERVIEW • SUSTAINABILITY • FINANCIAL REVIEW Investor Relations Contacts Thomas Steenbech Bomhoff Martin Riise Klaus Sindahl Mobile (DK):+45 3077 1226 Mobile (USA): +1 919 649 2565 Mobile (DK): +45 5363 0134 E-mail: tsbm@novozymes.com Mob
Slide 59: Novozymes – Rethink Tomorrow
novozymes’ | Rethink Tomorrow